Literature DB >> 10445668

Okadaic acid and anisomycin are protective and stimulate the SAPK/JNK pathway.

M Barancik1, P Htun, W Schaper.   

Abstract

We report that okadaic acid (OA), a known inhibitor of Ser/Thr phosphatases, protects pig myocardium against ischemic injury in an in vivo model and stimulates the activities of stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). When OA was directly infused into the subsequently ischemic myocardium for 60 min before a 60-min period of coronary occlusion followed by reperfusion, infarct size was reduced from a control value of 83.4 +/- 2.8% of the risk region to 40.7 +/- 9.1%. When OA was infused for 10 min before a 5-min occlusion and during 45 min thereafter, infarct size was reduced to 26.5%. In a separate set of similar experiments, we pretreated pig hearts in vivo with the protein-synthesis inhibitor and known activator of SAPK/JNK, anisomycin (AN), and found that this compound also significantly reduced infarct size from 83.4 +/- 2.8.1% to 48.1 +/- 5.1%. For in vitro assays, OA (600 nM), AN (500 microM), or solvent (KHB) were locally infused into the left ventricular myocardium, and biopsies from in situ beating hearts were obtained after 10, 30, and 60 min of infusion. The activities of Ser/Thr phosphatases (PPases), especially PP-2A, were significantly decreased after OA infusion. OA infusion increased the activity (in-gel phosphorylation of N-terminal c-Jun1-135) of both 46- and 55-kDa SAPK/JNKs (twofold to threefold, 30 and 60 min of infusion), and this increase correlated well with the observed decrease of PPase activities. Western blot analysis with a phosphospecific SAPK/JNK (Thr 183/Tyr 185) antibody showed an increased content of the phosphorylated forms after OA treatment. We observed significant stimulation of SAPK/JNK activity also after AN treatment (threefold to fourfold, after 30 min of infusion). In contrast to the SAPK/JNKs, the infusion of both OA and AN did not significantly change the activities and phosphorylation of extracellular signal-related kinases (ERKs) and p38-MAPK. The findings that the protective effect of both OA and AN correlates with increased activity of SAPK/JNKs suggest the involvement of these enzymes in the mechanism of cardioprotection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445668     DOI: 10.1097/00005344-199908000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components.

Authors:  D Nihalani; D Meyer; S Pajni; L B Holzman
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

Review 2.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

3.  Anisomycin protects cortical neurons from prolonged hypoxia with differential regulation of p38 and ERK.

Authors:  Soon-Sun Hong; Hong Qian; Peng Zhao; Alia Bazzy-Asaad; Ying Xia
Journal:  Brain Res       Date:  2007-03-01       Impact factor: 3.252

4.  Inability of serotonin to activate the c-Jun N-terminal kinase and p38 kinase pathways in rat aortic vascular smooth muscle cells.

Authors:  A K Banes; R D Loberg; F C Brosius; S W Watts
Journal:  BMC Pharmacol       Date:  2001-10-08

5.  c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas.

Authors:  Dieter H Heiland; Roberto Ferrarese; Rainer Claus; Fangping Dai; Anie P Masilamani; Eva Kling; Astrid Weyerbrock; Teresia Kling; Sven Nelander; Maria S Carro
Journal:  Oncotarget       Date:  2017-01-24

6.  Ajuba family proteins link JNK to Hippo signaling.

Authors:  Gongping Sun; Kenneth D Irvine
Journal:  Sci Signal       Date:  2013-09-10       Impact factor: 8.192

7.  Effect of okadaic acid on cultured clam heart cells: involvement of MAPkinase pathways.

Authors:  Houda Hanana; Hélène Talarmin; Jean-Pierre Pennec; Mickael Droguet; Julie Morel; Germaine Dorange
Journal:  Biol Open       Date:  2012-09-25       Impact factor: 2.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.